Dutasteride (5-ARI) extends time to d... - Prostate Cancer N...

Prostate Cancer Network

4,999 members3,124 posts

Dutasteride (5-ARI) extends time to disease progression in Low-Risk men on Active Surveillance, compared to Placebo

janebob99 profile image
9 Replies

This study by Finelli et al. (2010) looks at the effect of Dutasteride (5-ARI) on the rate of prostate cancer disease progression in Low-Risk men on Active Surveillance. The use of a 5-ARI was associated with a significantly lower rate of pathologic disease progression and lower rate of abandonment of active surveillance. 19% of men in the Dutasteride group experienced pathologic disease progression, compared to 37% in the placebo group, after 38 months. (p = 0.001).

pubmed.ncbi.nlm.nih.gov/212...

Written by
janebob99 profile image
janebob99
To view profiles and participate in discussions please or .
Read more about...
9 Replies
witantric profile image
witantric

How much is the PSA drop because the size of the prostate gets smaller?

janebob99 profile image
janebob99 in reply to witantric

That's a good question. I don't think anyone has reported what fraction of the total PSA drop is attributed to shrinkage of the prostate versus shrinkage of the tumor(s). We know that the prostate shrinks by 25% and the tumor shrinks by 30%, so the PSA split may be 60/40 or 50/50. However, tumors are more dense than healthy prostate tissue, so they may produce proportionately more PSA than healthy prostate tissue. So, the split could be 70/30 or 80/20.

dhccpa profile image
dhccpa

Have you talked to your MO about using dutasteride? The info you post looks interesting. I assume it's cheap but much resisted among oncologists for use in PCa.

janebob99 profile image
janebob99 in reply to dhccpa

My MO doesn't know anything about Dutasteride. She's young (~35), and I don't think they teach 5-alpha reductase inhibitors in medical school anymore.

My PCP did prescribe Dutasteride for me, because my DHT was unusually high.

I read recently that Prostate Cancer increases the amount of 5-alpha reductase enzyme, which, in turn, causes higher levels of DHT.

My PSA has dropped 76%, from10 to 2.4 over the past 4 months on Dutasteride monotherapy (no ADT or RT or RP). So, it's a real thing.

Unfortunately, about 30% of men with PCa don't respond to Dutasteride, so that may be why it's not prescribed more often. But, 70% of men do respond, which is good odds.

Bob

dhccpa profile image
dhccpa in reply to janebob99

Thanks. I was reading about natural substances that reduce 5-alpha reductase, although probably weakly.

NanoMRI profile image
NanoMRI

Nine years since my diagnosis, initially G 3+3, and I am still puzzled by the oxymoron progression of 'low-risk' prostate cancer. All the best to all of us trying to find our best path to beating this beast.

j-o-h-n profile image
j-o-h-n in reply to NanoMRI

Unfortunately, our best path is in the shape of a greyhound race track....and we're the mechanical "Rusty" rabbit.

Good Luck, Good Health and Good Humor.

j-o-h-n

NanoMRI profile image
NanoMRI in reply to j-o-h-n

Appreciate the humor. The track has not appealed to me which is why I strive to keep of the most common track, named standard of care.

well-wisher profile image
well-wisher

Your experience and observations about PSA levels and prostate/tumor shrinkage on Dutasteride are quite insightful. The differentiation in PSA drop due to prostate versus tumor shrinkage is indeed an important consideration. Given that tumors tend to be denser and potentially produce more PSA per unit volume than healthy prostate tissue, the PSA split you mentioned could very well be skewed towards a higher tumor contribution.

Regarding the prescription practices, it's interesting that your MO isn't familiar with Dutasteride. It highlights a potential gap in current medical training or perhaps a focus shift towards newer treatments. It’s great that your PCP recognized the potential benefit of Dutasteride given your high DHT levels.

Your significant PSA drop is a promising result, emphasizing Dutasteride’s efficacy in many cases. The statistic that about 30% of men with PCa don't respond to Dutasteride is a crucial piece of information for setting realistic expectations and understanding its variable effectiveness.

Given the variability in response to Dutasteride, are there specific biomarkers or genetic factors that could predict which patients are more likely to benefit from this treatment? This could help tailor more personalized treatment plans and potentially improve outcomes.

Also, according to my experience, the highest quality Dutasteride works even more effectively, I order it from global-world-delivery.com/c... recommend it to everyone.

You may also like...

Adjuvant Interventions for Active Surveillance (AS)

buy 1 year of active surveillance). Here is my review and the considerations that men on AS should...

Gleason score change from 3+4 to 3+3 with perineural invasion noted under Active Surveillance

specifics: PATHOLOGIC DIAGNOSIS: A. RPZ A: Benign prostatic tissue. B. RPZ PL: PROSTATIC...

Dutasteride Reduces Tumor Volume by 30% after 6 months.

chart compares prostate cancer tumor volume measured by MRI, at baseline and at 6 months, comparing...

46M, diagnosed in April, approaching decision

2 with 3+4, aka Grade Group 2 Family History: Father had prostate cancer What I've done...

Take your time before deciding

very high risk prostate cancer (non-metastatic) is slow to progress. There are now several studies...